Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc. > Possible catalysts in Q3
View:
Post by StockHawk1 on Jan 19, 2023 4:55pm

Possible catalysts in Q3

The pharma development company Algernon Pharmaceuticals (AGN.c AGNPF) announced last week that it is planning to conduct the Phase 2b clinical study of its Ifenprodil drug.


The 180-patient 90-day study, which is set to begin in Q3, will test how AGN's drug aids patients with chronic cough. 


Considering that this could bring about catalysts for AGN later in the year, I think that now could be a good time to buy, especially if you are willing to hold for a while. Definitely worth looking into IMO. 


https://ca.finance.yahoo.com/news/algernon-pharmaceuticals-announces-plans-180-120000185.html

 
Be the first to comment on this post
Algernon Pharmaceuticals Inc.